Eribulin: A Novel Cytotoxic Chemotherapy Agent (June)
Ann Pharmacother. 2012 May 22;
Abstract
OBJECTIVE:To review the chemistry, pharmacology, pharmacokinetics, safety, and efficacy of eribulin (Halaven).
....Eribulin has also shown activity in Phase 2 studies in other types of cancers, such as non-small cell lung cancer, prostate cancer, urothelial cancer, soft tissue sarcomas, and platinum-susceptible ovarian, fallopian tube, or peritoneal cancers........
